The effect of morphine and fentanyl use in patients with corona

Investigating the effect of morphine and fentanyl use in patients with new coronavirus (COVID-19)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150725023332N4

Enrollment

Registered

2021-03-08

Start date

2020-04-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-COV-2. Coronavirus infection, unspecified

Interventions

Intervention 1: First intervention group: Morphine group (20 patients): 3 mg of morphine (Product of Faran Shimi Pharmaceutical Company) is given intravenously every 6 hours for 5 days. Intervention 2

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Liver enzymes <2 times the normal range No intubation Evidence of new coronavirus (COVID-19) (clinical or paraclinical)

Exclusion criteria

Exclusion criteria: Sensitivity to opium Addiction to opium Addiction to alcohol

Design outcomes

Primary

Measure	Time frame
C-Reactive Protein (CRP). Timepoint: Before applying the intervention, then 24 hours and 48 hours after the intervention. Method of measurement: Biochemical tests (spectrophotometric method).;Immunoglobulin G (IgG). Timepoint: Before applying the intervention, then 24 hours and 48 hours after the intervention. Method of measurement: Immunological tests (competitive ELISA method).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Jahangirifard

Shahid Beheshti University of Medical Sciences

alirezajahangiri@sbmu.ac.ir+98 21 2610 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026